Skip Navigation



Rheumatology Advance Access published online on July 31, 2006
Rheumatology, doi:10.1093/rheumatology/kel250
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/10/1307    most recent
kel250v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yüksel, S.
Right arrow Articles by Ekim, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yüksel, S.
Right arrow Articles by Ekim, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Accepted June 6, 2006

Letter to the Editor

Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever

S. Yüksel 1, F. Yalçinkaya 1 *, B. Acar 1, Z. B. Özçakar 1, B. Öztürk 1, and M. Ekim 1

1 Department of Paediatric Nephrology, Ankara University School of Medicine, Ankara, Turkey

* To whom correspondence should be addressed.
F. Yalçinkaya, E-mail: yalcinkaya{at}tr.net



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.